-
Hearing Teva in Talks to Buy Spectrum Pharma
Thursday, July 28, 2011 - 10:31am | 140According to a tweet from @markflowchatter, Financial Times Mergermarket is reporting that Teva (NASDAQ: TEVA) is in talks to purchase Spectrum Pharma (NASDAQ: SPPI). This article may include mentions of rumors, chatter, or unconfirmed information. Readers should beware that while unconfirmed...
-
Earnings Roundup
Thursday, July 28, 2011 - 8:42am | 1660Kellogg Co (NYSE: K) reported a 14% rise in its second-quarter profit. Kellogg reported its quarterly profit at $343 million, or $0.94 per share, up from $302 million, or $0.79 per share, in the year-ago period. Its sales climbed 11% to $3.39 billion. However, analysts were expecting a profit of $0...
-
UPDATE: Bristol-Myers Reports Upbeat Q2 Earnings, Raises 2011 Forecast
Thursday, July 28, 2011 - 8:10am | 89Bristol-Myers Squibb Co (NYSE: BMY) reported upbeat second-quarter earnings and lifted its 2011 projections. Bristol-Myers reported its quarterly earnings at $902 million, or $0.52 per share, down from $927 million, or $0.53 per share, in the year-earlier period. Its revenue surged 14% y/y to $5....
-
BYDUREON™ Reply Submitted to FDA
Thursday, July 28, 2011 - 8:02am | 362Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced that the companies have submitted their reply to a complete response letter issued in October 2010 by the U.S. Food and Drug Administration (FDA) regarding BYDUREON™ (...
-
Earnings Scheduled For July 28
Thursday, July 28, 2011 - 5:02am | 559Astrazeneca PLC (NYSE: AZN) is expected to report its Q2 EPS at $1.80 on revenue of $8.19 billion. Exxon Mobil Corporation (NYSE: XOM) is projected to report its Q2 EPS at $2.33 on revenue of $121.39 billion. Bristol-Myers Squibb Company (NYSE: BMY) is estimated to report its Q2 EPS at $0.55 on...
-
Stocks to Watch for Thursday 7/28/2011: Fresh 52 Week Highs and Lows
Thursday, July 28, 2011 - 2:37am | 3403Stocks trading at or near 52-week highs and lows provide excellent trading opportunities, as volatility tends to increase at such levels and entry/exit points become more clearly defined. The following stocks hit new 52-week highs in Wednesday's trading session (listed from highest total volume to...
-
Top Yield Stocks of Warren Buffett
Thursday, July 28, 2011 - 1:19am | 385Last month, eBay (EBAY) held an auction of a lunch with the famous billionaire investor Warren Buffett, head of Berkshire Hathaway (BRK-A) (BRK-B). The high bid at the auction was $2,345,678. With Buffett's outstanding track record, and investors willing to pay millions to have lunch with him to...
-
Dr. Reddy's Announces the Launch of Gemcitabine for Injection
Wednesday, July 27, 2011 - 1:27pm | 80Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Gemcitabine for Injection (200 mg/vial and 1 g/vial), a bioequivalent generic version of Gemzar®* in the US market on July 25, 2011, following the approval by the United States Food & Drug Administration (USFDA) of Dr....
-
Wednesday's Put/Call Ratio Leaders
Wednesday, July 27, 2011 - 12:56pm | 78Here are today's Put/Call Ratio leaders… 1. Liberty Media (NASDAQ: LINTA) 12,100 puts, 38 calls 2. Collective Brands (NYSE: PSS) 4,398 puts, 53 calls 3. CarMax Group (NYSE: KMX) 5,724 puts 84 calls 4. Telvent GIT SA (NASDAQ: TLVT) 2,910 puts, 50 calls 5. Warner Chilcott (NASDAQ: WCRX) 3,067 puts,...
-
Questcor Pharmaceuticals up Nearly 26% on Upbeat Earnings
Wednesday, July 27, 2011 - 11:49am | 52Questcor Pharmaceuticals (NASDAQ: QCOR) is up nearly 26% on the upbeat earnings that were announced yesterday after the close. The company reported Q2 EPS of $0.23 vs. $0.20 Est. and revenues of $46M vs. $41.75M Est. Questcor Pharmaceuticals is currently trading at $32.64, or a gain of $6.64 or 25...
-
Calls Purchased on Questcor Pharmaceuticals
Wednesday, July 27, 2011 - 10:13am | 117Shares of Questcor Pharmaceuticals (NASDAQ: QCOR) are higher on the session by 20.00%, currently trading at $31.20. The stock has been moving largely higher over the past five months and is currently trading above the 200-day moving average. Options traders are buying calls on the name today. A...
-
Piper Jaffray Comments On Watson Pharmaceuticals
Wednesday, July 27, 2011 - 8:50am | 53According to Piper Jaffray, Watson Pharmaceuticals (NYSE: WPI), PT and rating are reiterated. Piper Jaffray has reiterated a PT of $78 and a rating of Overweight. EPS estimates are currently set at $4.44 for FY11 and $6.09 for FY12, with estimates nearing $7 for FY13. Watson closed yesterday at...
-
UPDATE: Oppenheimer Raising Its Price Target On Questcor Pharmaceuticals
Wednesday, July 27, 2011 - 8:47am | 163Oppenheimer & Co. is out with a research report on Questcor Pharmaceuticals (NASDAQ: QCOR) and is raising its price target to $35 and is keeping its Outperform rating on shares. In a note to clients, Oppenheimer & Co. writes, "On 7/26, QCOR reported 2Q11 adjusted EPS of $0.23, above our $0...
-
Earnings Roundup
Wednesday, July 27, 2011 - 8:43am | 1811Boeing Co (NYSE: BA) reported a 20% rise in its second-quarter profit. Boeing's quarterly profit surged to $941 million, or $1.25 per share, from $787 million, or $1.06 per share, in the year-earlier period. Its revenue gained 6% y/y to $16.54 billion from $15.57 billion. However, analysts were...
-
Oppenheimer Price Target and Rating Updates 7/27/11
Wednesday, July 27, 2011 - 8:41am | 287Oppenheimer made a number of price target and rating updates in a research report published today. Amazon (NASDAQ: AMZN) had its rating reiterated at Outperform. At the same time, its price target was raised from $220 to $250. On Tuesday, AMZN closed the day at $214.18. Its shares added 5.66% to...